In addition, we noticed that the expression of LAG3 and GZMK is higher than that of immune inhibitors, such as PD-L1, TIM3, and CTLA4, in the CD8+ T_3 cluster; thus, LAG3 or GZMK may be a better target for tumor immunotherapy in ccRCC. Here, GZMK is linked to neoplasm.